Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24935467 | 0.93 | CHEK1 (0.47) | KCNH2CHEK1ACACBACACAHSD17B10 | |
| SCHEMBL24936204 | 0.87 | CHEK1 (0.45) | KCNH2CHEK1HSD17B10GFERL3MBTL1 | |
| SCHEMBL24936198 | 0.84 | CHEK1 (0.47) | KCNH2CHEK1 | |
| SCHEMBL30522667 | 0.83 | KCNH2 (0.66) | KCNH2CHEK1DRD2 | |
| SCHEMBL24936161 | 0.83 | KCNH2 (0.66) | KCNH2CHEK1DRD2 | |
| SCHEMBL24936282 | 0.82 | KCNH2 (0.77) | KCNH2CHEK1 | |
| SCHEMBL31188683 | 0.79 | KCNH2 (0.35) | KCNH2CHEK1ACACBACACAL3MBTL1 | |
| SCHEMBL24936150 | 0.78 | KCNH2 (0.57) | KCNH2CHEK1DRD2 | |
| SCHEMBL24936172 | 0.76 | CHEK1 (0.72) | KCNH2CHEK1 | |
| SCHEMBL24936266 | 0.76 | KCNH2 (0.53) | KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | KCNH2 2700/4885CHEK1 1/4885ACACB 3588/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | KCNH2 2700/4885CHEK1 1/4885ACACB 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.